Associate Scientist II (Contract), Research
VaxcyteHighlight
Summary
About the Role
About You
- BS in Chemistry, Biochemistry, or related field with minimum 2 years of relevant industry experience.
- Extensive hands-on experience in purification methods such as diafiltration, depth filters, and TFF.
- Proficiency with analytical techniques including SDS-PAGE, Western blotting, ELISA, HPLC, and SEC-MALS.
- Prior hands-on experience in conjugation process development.
- Experience with vaccines, carbohydrates, or protein.
- Strong understanding of scientific concepts, process development, and analytical assay principles.
Benefits
- Competitive hourly wage ranging from $51.00 to $56.00.
- Opportunity to work in a dynamic and innovative environment focused on vaccine development.
Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. VAX-31, our 31-valent pneumococcal conjugate vaccine (PCV) candidate advancing to a Phase 3 adult clinical program and currently being evaluated in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, our 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice. We are re-engineering the way highly complex vaccines are made. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. In addition to our PCV franchise, our pipeline includes early-stage programs targeting Group A Strep, periodontitis and Shigella. At Vaxcyte, we are driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.